Compare Ascendis Pharma A/S (ASND) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs MINISO Group Holding Ltd — how do they compare? Ascendis Pharma A/S trades at $253.35 (market cap $16.67B), while MINISO Group Holding Ltd trades at $11.9 (market cap $3.62B). The key difference: Ascendis Pharma A/S is far larger — about 4.6× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MNSO | |
|---|---|---|
Market Cap | $16.67B | $3.62B |
Sector | Health | Technology |
52-Week High | $277.18 | $26.63 |
52-Week Low | $189.74 | $11.30 |
Enterprise Value | $17.04B | $4.29B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
MNSO trades at $11.9, down 4.95% in the last session, with a neutral technical signal and bearish moving averages. Recent earnings showed a Q1 2026 beat but prior misses, while fundamentals include a P/E of 12.16 and net margin of 8.98%. The company announced a $2 billion share repurchase in June 2026, supporting sentiment amid mixed performance.
Outlook is cautiously optimistic with 75% analyst buy ratings, but risks include margin pressure from SG&A costs and competitive retail markets. The stock offers value if earnings growth sustains, though volatility from recent declines warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
